Embecta Corp.
NASDAQ:EMBCDrug Manufacturers - Specialty & Generic
+$0.02 today
- Market cap
- $345.06M
- Beta
- 0.81
- P/E (TTM)
- 1.6
- EPS (TTM)
- $1.92
- Dividend yield
- 14.79%
Volume 0.72M
Average 1.95M
EMBC EBITDA
Earnings before interest, taxes, depreciation, and amortization; a proxy for operating profit before non-cash and financing charges.
Embecta Corp.NASDAQ: EMBC
EBITDA · Q2 FY2026 · quarter ended Mar 2026
EBITDA dips below year-ago levels
Q2 FY2026 EBITDA of $44.9M fell 39.5% year over year, behind the +51.1% change in trailing-twelve-month EBITDA. Sequentially, it fell 53.2% from the prior quarter. Over 3 fiscal years it compounded at -4.1% a year.
Context
- EBITDA amounted to 27.3% of revenue in FY2025, up 9.6 pp from a year earlier.
- EBITDA increased in 1 of the last 3 fiscal years.
What to watch
Whether EBITDA reaches the consensus estimate from 3 analysts of $277.39M (-5.9%) for the fiscal year ending Sep 2026, a slowdown from the +48.1% reported in FY2025.
Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.
- Latest quarterMar 2026
- $44.9M-53.2% QoQ
- Last fiscal yearSep 2025
- $294.7M+48.1% YoY
- LTMMar 2026
- $322.2M+51.1% YoY
| Horizon | Past | Forecast | Difference |
|---|---|---|---|
| Quarter | -39.5% | -49.2% | -9.7 pp |
| 1 year | +48.1% | -5.9% | -54.0 pp |
| 3-year CAGR | -4.1% | -2.7% | +1.4 pp |
| 5-year CAGR | +4.0% | — | |
| 10-year CAGR | — | — |
Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.
EBITDA history
USD · from the income statement
- Latest · FY2025
- 294.7M USD
- Year-over-year change
- +48.1%
- 4-year CAGR
- -13.8%
| Period | Period end | EBITDA | YoY change |
|---|---|---|---|
| FY2025 | 2025-09-30 | 294.7M | +48.1% |
| FY2024 | 2024-09-30 | 199M | -18.9% |
| FY2023 | 2023-09-30 | 245.4M | -26.6% |
| FY2022 | 2022-09-30 | 334.5M | -37.2% |
| FY2021 | 2021-09-30 | 533M | — |
EBITDA vs competitors
How EMBC compares with its peers on the latest reported figures
- EMBC's LTM Mar 2026 EBITDA of $322.2M is the highest of the 11 companies compared; the peer median is -$70.55M.
- Its year-over-year change of +51.1% is the 3rd highest of 11, against a peer median of -7.1%.
- EBITDA amounts to 30.9% of revenue for EMBC, versus a peer median of 34.8%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $322.2M | +51.1% | -4.1% | 30.9% | |
| LTM Mar 2026 | $154.5M | +28.1% | +148.3% | 22.8% | |
| LTM Mar 2026 | $27.5M | -56.2% | -11.5% | 29.3% | |
| LTM Jun 2026 | $15.56M | +159.1% | — | 3.4% | |
| LTM Mar 2026 | -$51.63M | -40.6% | — | 102.7% | |
| LTM Jun 2026 | -$55.57M | +77.9% | — | 26.6% | |
| LTM Mar 2026 | -$85.53M | -16.7% | — | 132.6% | |
| LTM Mar 2026 | -$190.9M | +2.4% | — | 4732.2% | |
| LTM Mar 2026 | -$314.51M | -1056.6% | — | 16.7% | |
| LTM Mar 2026 | -$334.2M | -423.0% | — | 40.3% | |
| LTM Mar 2026 | -$438.52M | +24.4% | — | 669.6% | |
| Peer median (excluding EMBC) | -$70.55M | -7.1% | +68.4% | 34.8% | |
Competitors are the stored peer set for EMBC. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Sep 2021 | FY2022 Sep 2022 | FY2023 Sep 2023 | FY2024 Sep 2024 | FY2025 Sep 2025 |
|---|---|---|---|---|---|
| Revenue | 1.17B | 1.13B | 1.12B | 1.12B | 1.08B |
| Cost of Revenue | 365M | 354.6M | 370.9M | 394.2M | 400.9M |
| Gross Profit | 800M | 774.9M | 749.9M | 728.9M | 679.5M |
| Gross Margin | 68.7% | 68.6% | 66.9% | 64.9% | 62.9% |
| Research & Development | 63M | 65M | 85.2M | 78.8M | 21.5M |
| Selling, General & Admin | 240.3M | 294.8M | 341.3M | 365.1M | 331.4M |
| Operating Expenses | 308M | 396.8M | 520.3M | 554.7M | 350.2M |
| Depreciation & Amortization | 38M | 31.7M | 32.7M | 42.5M | 51.1M |
| EBITDA | 533M | 334.5M | 245.4M | 199M | 294.7M |
| EBITDA Margin | 45.8% | 29.6% | 21.9% | 17.7% | 27.3% |
| Operating Income | 492M | 378.1M | 229.6M | 174.2M | 329.3M |
| Operating Margin | 42.2% | 33.5% | 20.5% | 15.5% | 30.5% |
| Interest Income | 0 | 0 | 0 | 0 | 0 |
| Interest Expense | 0 | 46.2M | 107M | 112.3M | 107.3M |
| Other Income / Expenses | 3M | (121.5M) | (123.9M) | (130M) | (193M) |
| Income Before Tax | 495M | 256.6M | 105.7M | 44.2M | 136.3M |
| Pre-Tax Margin | 42.5% | 22.7% | 9.4% | 3.9% | 12.6% |
| Income Tax Expense | 80M | 33M | 35.3M | (34.1M) | 40.9M |
| Net Income | 414.8M | 223.6M | 70.4M | 78.3M | 95.4M |
| Net Margin | 35.6% | 19.8% | 6.3% | 7.0% | 8.8% |
| EPS (Basic) | 7.31 | 3.92 | 1.23 | 1.36 | 1.64 |
| EPS (Diluted) | 7.31 | 3.89 | 1.22 | 1.34 | 1.62 |
| Weighted Avg Shares | 56.8M | 57.06M | 57.24M | 58.43M | 58.31M |
| Weighted Avg Shares (Diluted) | 56.8M | 57.06M | 57.76M | 58.33M | 58.92M |
Embecta Corp.
NASDAQ:EMBC
Intrinsic Alpha fair value
Locked
Current Price
$6.09
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.